公开(公告)号：EP1411968B1

公开(公告)日：2008-09-17

申请号：EP02748271.0

申请日：2002-07-30

申请人： THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES

发明人： GREIG, Nigel, H. ,  EGAN, Josephine ,  DOYLE, Maire ,  HOLLOWAY, Harold ,  PERRY, Tracy, Ann

IPC分类号： A61K38/10 ,  A61K38/16 ,  C07K7/00 ,  C07K14/00 ,  C07K14/605 ,  A61K38/26

CPC分类号： C07K14/575 ,  A61K38/00 ,  A61K38/2278 ,  A61K38/26 ,  C07K14/57563

摘要： The invention relates to novel polypeptide analogues of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or extendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogues thereof for neuroprotective and neurotrophic effects.

公开(公告)号：EP1349858A2

公开(公告)日：2003-10-08

申请号：EP01989211.6

申请日：2001-11-02

申请人： THE GOVERNMENT OF THE UNITED STATES OF AMERICA,as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES ,  Message Pharmaceuticals

发明人： GREIG, Nigel, H. ,  SHAW, Karen, T., Y. ,  YU, Qiang-Sheng ,  HOLLOWAY, Harold, W. ,  UTSUKI, Tada ,  SONCRANT, Timothy, T. ,  INGRAM, Donald, S. ,  BROSSI, Arnold ,  GIORDANO, Anthony ,  POWERS, Gordon ,  DAVIDSON, Diane ,  STURGESS, Michael

IPC分类号： C07D487/00

CPC分类号： C07D487/04 ,  A61K31/325 ,  A61K31/343 ,  A61K31/345 ,  A61K31/381 ,  A61K31/382 ,  A61K31/403 ,  A61K31/405 ,  A61K31/407 ,  C07D209/16 ,  C07D209/34 ,  C07D209/36 ,  C07D209/38 ,  C07D277/82 ,  C07D453/04 ,  C07D471/04 ,  C07D487/08 ,  C07D491/04 ,  C07D495/04

摘要： The present invention provides compounds and methods of administering compounds to a subject taht can reduce βAPP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce βAPP production and that is not tocix in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease βAPP production.

公开(公告)号：EP1411968A2

公开(公告)日：2004-04-28

申请号：EP02748271.0

申请日：2002-07-30

申请人： THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES

发明人： GREIG, Nigel, H. ,  EGAN, Josephine ,  DOYLE, Maire ,  HOLLOWAY, Harold ,  PERRY, Tracy, Ann

IPC分类号： A61K38/10 ,  A61K38/16 ,  C07K7/00 ,  C07K14/00

CPC分类号： C07K14/575 ,  A61K38/00 ,  A61K38/2278 ,  A61K38/26 ,  C07K14/57563

摘要： The invention relates to novel polypeptide analogues of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or extendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogues thereof for neuroprotective and neurotrophic effects.